Ed J. Gane

Auckland, AUK, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury.

ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury.

Journal: Journal of viral hepatitis

Published: December 12, 2025

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.

Journal: Antiviral therapy

Published: November 21, 2025

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal: Journal of hepatology

Published: November 05, 2025

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal: Journal of hepatology

Published: November 05, 2025

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

Journal: The New England journal of medicine

Published: September 26, 2025

Updated hepatitis C modelling in Aotearoa New Zealand: a lower burden, but clearer elimination targets.

Updated hepatitis C modelling in Aotearoa New Zealand: a lower burden, but clearer elimination targets.

Journal: The New Zealand medical journal

Published: August 14, 2025

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.

Journal: The lancet. Gastroenterology & hepatology

Published: April 21, 2025

Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells.

Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells.

Journal: Journal of hepatology

Published: January 10, 2025

Liver Transplantation in Well-Selected Class III Obese Recipients Yields Good Outcomes.

Liver Transplantation in Well-Selected Class III Obese Recipients Yields Good Outcomes.

Journal: Clinical transplantation

Published: May 28, 2024

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

Journal: The Lancet. Oncology

Published: May 15, 2024

Reinfection incidence and risk among people treated for recent hepatitis C virus infection.

Reinfection incidence and risk among people treated for recent hepatitis C virus infection.

Journal: AIDS (London, England)

Published: July 19, 2023

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 16, 2023

Showing 1-12 of 66

Last Updated: 09/26/2026